Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
April 2024
The medical devices information portal connecting healthcare professionals to global vendors
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy
Xyall launches Tissector High Throughput system, a world-first automated tissue dissector
, /in Product News /by panglobalXyall BV, a leading MedTech innovator in molecular pathology, has launched its Tissector High Throughput (HT) system for greater diagnostic precision. The Netherlands-based company says this is a world first – enabling high volume, molecular diagnostic laboratories to capitalize commercially on the company’s unique, automated, tissue dissection technology.
Xyall‘s Tissector HT solution uses state-of-the-art technology, image registration, robotics and workflow optimization. It is designed for continuous operation and is fully integrated with digital pathology solutions and the laboratory workflow system (LIMS). The Tissector HT can hold 1,800 slides, dissect a minimum of 80 dissection slides per hour with an accuracy of < 0.1 mm and is designed for three hours unattended operation. The system is easy to use, combining high throughput with the highest accuracy.
Tissue dissection, even in large-scale commercial labs, remains a manual, labour-intensive process at risk of error and cross contamination. “The Xyall solution provides the missing link for customers,” explained Guido Du Pree, Xyall’s CEO.
Current practice involves manually pen-marking Regions of Interest (ROIs) on Hematoxylin & Eosin (H&E) stained slides. Using visual assessment, lab technicians then translate these ROIs into dissection slides, manually scraping the tissue and placing it in small containers.
Order-to-built systems
“Xyall has already won contracts for order-to-built systems from two of the largest laboratories in the US, with high levels of interest from other molecular diagnostic laboratories requiring industrial-sized platforms,” said Du Pree.
“With new therapies coming to the market, and transformative technologies in PCR and next generation sequencing, precision medicine is being revolutionized – providing physicians and patients with the highest quality information about their health.
“However, tissue dissection to enable molecular profiling is still a labour intense, subjective process. Our pioneering technology transforms how this is done – delivering greater accuracy, consistency and overall improved quality control.”
Table-top version for hospital-based labs
Alongside the new large-scale, industrial system, Xyall is developing a smaller, table-top version for hospital-based molecular pathology laboratories. Based on the same technology, the company expects to have this second system commercially available in Q1 2022.
Du Pree added: “Worldwide shortages of experienced pathology staff are already putting labs under pressure. The Xyall solution will address this, helping customers to make more efficient use of existing, and increasingly scarce, staffing levels.”
Macron, Ghebreyesus break ground for new WHO Academy in Lyon
, /in E-News /by panglobalA 3D rendering of the Library at the WHO Academy in Lyon, France. © ateliers 2/3/4/
French president Emmanuel Macron, and WHO Director-General Dr Tedros Adhanom Ghebreyesus, today broke ground for the WHO Academy’s campus in the French city of Lyon.
The event fulfils a commitment by the two leaders to establish a WHO Academy in Lyon’s bio-medical district to meet the needs of WHO Member States and a growing global health workforce to provide for expanded access to life-long learning, health guidance and competency-building.
Designed for collaborative learning
When it opens in 2024, the WHO Academy campus in Lyon will have high-tech and people-centred spaces designed for collaborative learning, educational research and innovation. It will also host a world-class health emergencies simulation centre that will use advanced technologies to enable health workers to sharpen their competencies amid realistic scenarios including mass casualties and disease outbreaks.
A 3D rendering of the exterior of the WHO Academy in Lyon, France. © ateliers 2/3/4/
During today’s event at Lyon’s Cité Internationale, President Macron and Dr Tedros reviewed an architectural model of the building and talked via video-link with health workers who have participated in the Academy’s Mass Casualty Management programme, which is already operating in several countries including France, Greece, Afghanistan, Ethiopia and Somalia.
The quickening pace of scientific discovery and advancement of technology is making it more difficult for health workers, policy makers and other public health practitioners to keep up with evidence-based health practice and policy. As a result, it often takes more than a decade to put important life-saving guidelines into practice.
From its campus in Lyon, the Academy will offer multilingual, personalized learning programmes in digital, in-person and blended formats, deploying the latest evidence-based health guidance, state-of-the-art learning technologies and advancements in the science of adult learning.
Resilience during a health crisis
“The ambitions of the WHO Academy are not modest: to transform lifelong learning in health globally,” said Dr Tedros. “The COVID-19 pandemic is a powerful demonstration of the value of health workers, and why they need the most up-to-date information, competencies and tools to keep their communities healthy and safe.”
He added: “The WHO Academy is an investment in health, education, knowledge and technology, but ultimately it’s an investment in people, and in a healthier, safer, fairer future.”
“The quality of the health workforce is the key to resilience during a health crisis,” said President Macron. “Investing in health systems is the best way to prepare for future pandemics. Success requires unprecedented coordination of all actors. WHO is, of course, a key player and its Academy will be an essential platform for disseminating learning.”
A 3D rendering of the exterior of the WHO Academy in Lyon, France. © ateliers 2/3/4/
The Academy aims to expand access to critical learning to health workers, managers, public health officials, educators, researchers, policy makers and people who provide care in their own homes and communities, as well as to WHO’s own workforce throughout the world. The vast majority will use online means to access the Academy’s programmes, which will be made available via desktop and mobile devices and in low-bandwidth settings, thereby ensuring an equitable, global and diverse cohort of learners.
Additionally, the WHO Academy will:
WHO Academy’s Executive Director
WHO also used the occasion to announce the appointment, which became effective on 16 August 2021, of Dr Agnès Buzyn as the Academy’s Executive Director. She has been serving since January as the WHO Director-General’s Envoy for Multilateral Affairs, during which time she has also supervised the Academy project.
Lead investor
As a WHO Member State and a key actor in global health, France is the lead investor in the Academy’s development, having committed more than €120 million to support its establishment and infrastructure. This achievement is possible thanks to the collective actions, commitment and financial support of the City of Lyon and the Lyon Metropole, as well as from the Auvergne-Rhône-Alpes region, which contributed €25 million of the total investment. The region will own the campus and lease it to WHO.
FDA approves first interchangeable biosimilar insulin product for treatment of diabetes
, /in E-News /by 3wmediaThe US FDA has approved the first interchangeable biosimilar insulin product, indicated to improve glycaemic control in adults and paediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus.
Researchers establish novel approach for developing new antibiotics
, /in E-News /by panglobalResearchers at Children’s Hospital of Philadelphia (CHOP) have developed a novel method for producing new antibiotics to combat resistant bacteria. Through an approach that would target bacteria with an antibiotic that is masked by a prodrug, which the bacteria would themselves remove, the researchers identified a method that would allow for development of new, effective […]
Dynamic heart model advances engineered heart tissue tech
Cardiology, /in Events /by panglobalThe Feinberg research group at Carnegie Mellon University, along with collaborators in the Netherlands, has developed a dynamic heart model comprised of engineered heart muscle tissue designed to mimic physiologic preloads and afterloads.
Scientists test customized wound dressings made from tropoelastin
, /in E-News /by panglobalCustomized, biomedically applicable materials based on tropoelastin are being developed in a joint project by Skinomics from Halle, Martin Luther University Halle-Wittenberg and the Fraunhofer Institute for Microstructure of Materials and Systems IMWS. The material combines biocompatibility, durability, biodegradability and favourable mechanical properties similar to those of skin. Preclinical tests have confirmed that it is […]
Researchers find gene therapy provides neuroprotection to prevent glaucoma vision loss
, /in E-News /by panglobalA form of gene therapy protects optic nerve cells and preserves vision in mouse models of glaucoma, according to research supported by NIH’s National Eye Institute. The findings suggest a way forward for developing neuroprotective therapies for glaucoma, a leading cause of visual impairment and blindness. The report was published in Cell [1].
Researchers find gene therapy provides neuroprotection to prevent glaucoma vision loss
, /in E-News /by 3wmediaLorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla vulputate condimentum eros. Sed quis luctus leo. Pellentesque pellentesque magna justo, vel ornare purus convallis id. Nunc a libero in sem vehicula pulvinar gravida mattis sem.
Physicians urged to take note of ethnicity-specific BMI guidelines
, /in E-News /by panglobalWhile body mass index (BMI) as a body composition assessment tool has long had its critics, recent research has highlighted a new potential drawback in that it could prevent people of certain ethnicities from having their risk for Type 2 diabetes assessed earlier. A psychologist and weight management specialist at Cleveland Clinic stresses the importance […]
Global economic recovery slowed by vaccine inequity
, /in E-News /by panglobalCovid-19 vaccine inequity will have a lasting and profound impact on socio-economic recovery in low- and lower-middle income countries without urgent action to boost supply and assure equitable access for every country, including through dose sharing, according to new data released recently by the United Nations Development Programme (UNDP), the World Health Organization (WHO) and […]